284 related articles for article (PubMed ID: 16432077)
1. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
Dubois D; Dhawan R; van de Velde H; Esseltine D; Gupta S; Viala M; de la Loge C
J Clin Oncol; 2006 Feb; 24(6):976-82. PubMed ID: 16432077
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Lee SJ; Richardson PG; Sonneveld P; Schuster MW; Irwin D; San Miguel JF; Crawford B; Massaro J; Dhawan R; Gupta S; Anderson KC
Br J Haematol; 2008 Nov; 143(4):511-9. PubMed ID: 18986387
[TBL] [Abstract][Full Text] [Related]
3. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis.
Viala M; Bhakar AL; de la Loge C; van de Velde H; Esseltine D; Chang M; Dhawan R; Dubois D
J Clin Epidemiol; 2007 Jul; 60(7):670-679. PubMed ID: 17573982
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.
Dawson MA; Opat SS; Taouk Y; Donovan M; Zammit M; Monaghan K; Horvath N; Roberts AW; Prince HM; Hertzberg M; McLean CA; Spencer A
Clin Cancer Res; 2009 Jan; 15(2):714-22. PubMed ID: 19147779
[TBL] [Abstract][Full Text] [Related]
6. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
[TBL] [Abstract][Full Text] [Related]
7. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin DH; Rajkumar SV; Srkalovic G; Alsina M; Anderson KC
Cancer; 2006 Mar; 106(6):1316-9. PubMed ID: 16470606
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM
Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
10. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; San Miguel JF; Cavenagh JD; Anderson KC
Br J Haematol; 2007 Jun; 137(5):429-35. PubMed ID: 17451408
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
13. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
15. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
16. [Bortezomib (Velcade) in relapsed/refractory multiple myeloma--the first experience in the Czech Republic].
Spicka I; Hájek R; Vytrasová M; Maisnar V; Gregora E; Schutzova M; Straub J; Scudla V; Adam Z; Klener P
Cas Lek Cesk; 2005; 144(9):636, 638-40. PubMed ID: 16193944
[TBL] [Abstract][Full Text] [Related]
17. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
[TBL] [Abstract][Full Text] [Related]
18. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Richardson PG; Mitsiades C; Ghobrial I; Anderson K
Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
[TBL] [Abstract][Full Text] [Related]
19. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.
Mikhael JR; Belch AR; Prince HM; Lucio MN; Maiolino A; Corso A; Petrucci MT; Musto P; Komarnicki M; Stewart AK
Br J Haematol; 2009 Jan; 144(2):169-75. PubMed ID: 19036114
[TBL] [Abstract][Full Text] [Related]
20. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
Kane RC; Farrell AT; Sridhara R; Pazdur R
Clin Cancer Res; 2006 May; 12(10):2955-60. PubMed ID: 16707588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
